GEP20084337B - - Google Patents

Info

Publication number
GEP20084337B
GEP20084337B GEAP200710221A GEAP2007010221A GEP20084337B GE P20084337 B GEP20084337 B GE P20084337B GE AP200710221 A GEAP200710221 A GE AP200710221A GE AP2007010221 A GEAP2007010221 A GE AP2007010221A GE P20084337 B GEP20084337 B GE P20084337B
Authority
GE
Georgia
Application number
GEAP200710221A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GEP20084337B publication Critical patent/GEP20084337B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/58—Derivatives of thiocarboxylic acids, the doubly-bound oxygen atoms being replaced by nitrogen atoms, e.g. imino-thio ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
GEAP200710221A 1998-06-04 2007-08-08 GEP20084337B (h)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8796398P 1998-06-04 1998-06-04

Publications (1)

Publication Number Publication Date
GEP20084337B true GEP20084337B (h) 2008-03-25

Family

ID=22208298

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP200710221A GEP20084337B (h) 1998-06-04 2007-08-08

Country Status (45)

Country Link
US (4) US6235764B1 (h)
EP (1) EP1084114B1 (h)
JP (2) JP3735254B2 (h)
KR (1) KR100392434B1 (h)
CN (2) CN1172918C (h)
AP (1) AP1309A (h)
AR (1) AR016725A1 (h)
AT (1) ATE275553T1 (h)
AU (1) AU3342199A (h)
BG (1) BG65104B1 (h)
BR (1) BR9910900B1 (h)
CA (2) CA2475113C (h)
CO (1) CO5011121A1 (h)
CZ (1) CZ298559B6 (h)
DE (1) DE69920009T2 (h)
EA (1) EA004935B1 (h)
ES (1) ES2226368T3 (h)
GE (1) GEP20084337B (h)
GT (1) GT199900070A (h)
HN (1) HN1999000080A (h)
HR (1) HRP20000835B1 (h)
HU (1) HUP0102422A3 (h)
ID (1) ID27006A (h)
IL (1) IL138776A0 (h)
IS (1) IS2269B (h)
MA (1) MA26638A1 (h)
MY (1) MY130668A (h)
NO (1) NO318798B1 (h)
NZ (1) NZ507009A (h)
OA (1) OA11504A (h)
PA (1) PA8472301A1 (h)
PE (1) PE20000568A1 (h)
PL (1) PL198151B1 (h)
PT (1) PT1084114E (h)
SA (1) SA99200217B1 (h)
SI (1) SI1084114T1 (h)
SK (1) SK286405B6 (h)
TN (1) TNSN99106A1 (h)
TR (1) TR200003478T2 (h)
TW (1) TW561154B (h)
UA (1) UA60365C2 (h)
UY (1) UY25619A1 (h)
WO (1) WO1999062890A1 (h)
YU (1) YU70100A (h)
ZA (1) ZA993752B (h)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849769A (en) * 1994-08-24 1998-12-15 Medivir Ab N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
WO1999010349A1 (en) 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TR200102969T2 (tr) 1999-04-15 2002-08-21 Bristol-Myers Squibb Company Siklik protein tirozin kinaz önleyicileri.
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
CN1427839A (zh) * 2000-03-16 2003-07-02 根索福特股份有限公司 含有核酸结合部分的带电荷化合物及其用途
US7078536B2 (en) 2001-03-14 2006-07-18 Genesoft Pharmaceuticals, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
BR0113139A (pt) 2000-08-09 2003-06-24 Agouron Pharma Compostos, seus sais, formas multiméricas, pró-drogas ou metabólitos, composições farmacêuticas, método de tratamento de uma doença ou disfunção mediana através da inibição de cdk4 ou um complexo de cdk4/ciclina, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase e método de modulação ou inibição da atividade de um receptor de proteìna cinase
AU2001286527A1 (en) 2000-08-17 2002-02-25 Lumera Corporation Design and synthesis of advanced nlo materials for electro-optic applications
DE60110802T2 (de) 2000-08-18 2005-10-06 Agouron Pharmaceuticals, Inc., San Diego Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
RU2264389C3 (ru) 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
OA12532A (en) * 2000-11-28 2006-06-02 Pfizer Prod Inc Salts of a isothiazole-4-carboxamide and their useas anti-hyperproliferation agents.
CA2432000C (en) 2000-12-21 2011-03-15 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
US6699866B2 (en) 2001-04-17 2004-03-02 Sepracor Inc. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
CA2483084A1 (en) 2002-05-02 2003-11-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
AU2003232551A1 (en) * 2002-06-13 2003-12-31 Qlt Inc. Methods of using isothiazole derivatives to treat cancer or inflammation
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
CA2493701A1 (en) * 2002-07-25 2004-02-05 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
EP1539151B1 (en) 2002-08-02 2009-03-18 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
EP1545519B1 (en) * 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
CA2503119A1 (en) 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
US7129214B2 (en) 2002-12-10 2006-10-31 Oscient Pharmaceuticals Corporation Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
BR0317548A (pt) 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
CA2513140A1 (en) * 2003-01-27 2004-08-12 Pfizer Products Inc. Isothiazole derivatives
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
GEP20084393B (en) * 2003-04-24 2008-06-10 Incyte Corp Aza spiro alkane derivatives as inhibitors of metalloproteases
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
DK1648998T3 (en) 2003-07-18 2015-01-05 Amgen Inc Specific binding agents for hepatocyte growth factor
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
WO2005081997A2 (en) * 2004-02-20 2005-09-09 The Scripps Research Institute Isothiazole based protein kinase inhibitors
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
RU2342159C2 (ru) 2004-07-16 2008-12-27 Пфайзер Продактс Инк. Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
CN101023064B (zh) 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
KR100893977B1 (ko) 2004-08-26 2009-04-20 화이자 프로덕츠 인코포레이티드 이소티아졸 유도체의 제조 방법
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
CN101001629B (zh) 2004-09-17 2010-05-05 卫材R&D管理有限公司 药物组合物
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
DE602006016085D1 (de) 2005-03-16 2010-09-23 Genentech Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
KR100990027B1 (ko) 2005-04-26 2010-10-26 화이자 인코포레이티드 Ｐ-카드헤린 항체
WO2007006760A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
TWI370137B (en) 2005-09-07 2012-08-11 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US7989631B2 (en) * 2006-02-10 2011-08-02 Amgen Inc. Hydrate forms of AMG706
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
JP5269762B2 (ja) * 2006-04-18 2013-08-21 アーディア・バイオサイエンシーズ・インコーポレイテッド Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
BRPI0711358A2 (pt) 2006-05-09 2011-09-27 Pfizer Prod Inc derivados do ácido cicloalquilamino e suas composições farmacêuticas
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
KR101051559B1 (ko) * 2006-06-08 2011-07-22 일라이 릴리 앤드 캄파니 Ｉ군 대사친화성 수용체 길항제로서의 치환된 카르복스아미드
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
US7977371B2 (en) * 2007-02-26 2011-07-12 Santen Pharmaceutical Co., Ltd. Pyrrole derivative having ureido group and aminocarbonyl group as substituents
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
WO2008127707A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
US8509487B2 (en) * 2007-04-19 2013-08-13 Avago Technologies General Ip (Singapore) Pte. Ltd. System and method for optically measuring a parameter of an object
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
NZ583282A (en) 2007-08-21 2012-09-28 Amgen Inc Human c-fms antigen binding proteins
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
AU2009329994B2 (en) 2008-12-23 2014-04-03 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
BRPI1006270B1 (pt) 2009-03-25 2022-08-16 Genentech, Inc Anticorpo anti-a5ss1, imunoconjugado, composição farmacêutica, método in vitro ou ex vivo para detectar a proteína a5ss1, uso de um anticorpo e kit para detectar a proteína a5ss1
WO2011008696A2 (en) 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
US20120128670A1 (en) 2009-07-31 2012-05-24 OSI Pharmaceuticals, LLC mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
KR101557545B1 (ko) 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
RU2609658C2 (ru) 2009-12-21 2017-02-02 Дженентек, Инк. Состав, содержащий антитело
MX343383B (es) 2010-02-12 2016-11-03 Pfizer Inc * Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
ES2695899T3 (es) 2010-06-16 2019-01-11 Univ Pittsburgh Commonwealth Sys Higher Education Anticuerpos contra endoplasmina y su uso
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
CN103261225A (zh) 2010-07-23 2013-08-21 波士顿大学董事会 作为用于抑制病理性血管生成和肿瘤细胞侵袭力的治疗剂以及用于分子成像和靶向递送的抗DEspR抑制剂
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
UA112539C2 (uk) 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
ES2851602T3 (es) 2011-12-28 2021-09-08 Allergan Inc Derivados de 3-fenil-5-ureidoisotiazol-4-carboxamida como inhibidores de cinasa
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103508961B (zh) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
ES2644758T3 (es) 2012-10-16 2017-11-30 Tolero Pharmaceuticals, Inc. Moduladores de PKM2 y métodos para su uso
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
CA2906057A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Antibody formulations
SG11201507316UA (en) 2013-03-14 2015-10-29 Panoptica Inc Ocular formulations for drug-delivery to the posterior segment of the eye
KR20210149232A (ko) 2013-03-14 2021-12-08 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
ES2727374T3 (es) 2014-04-04 2019-10-15 Crown Bioscience Inc Taicang Gen de fusión HNF4G-RSPO2
JO3783B1 (ar) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd مشتق كوينولين عالي النقاء وطريقة لإنتاجه
AU2015318001B2 (en) 2014-09-15 2021-03-25 Genentech, Inc. Antibody formulations
CA2958315A1 (en) 2014-09-17 2016-03-24 Panoptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
JP7041515B2 (ja) 2015-01-08 2022-03-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 骨、骨髄、及び軟骨の誘導を提供する因子及び細胞
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017022666A8 (pt) 2015-04-20 2022-10-18 Tolero Pharmaceuticals Inc Preparando resposta à alvocidib por perfilamento mitocondrial
CN107849073B (zh) 2015-05-18 2020-04-03 特雷罗药物股份有限公司 具有增加的生物利用度的阿伏西地前药
KR102705821B1 (ko) 2015-06-16 2024-09-12 가부시키가이샤 프리즘 바이오랩 항암제
CA2993659A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
MX2018006781A (es) 2015-12-03 2018-11-09 Agios Pharmaceuticals Inc Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN110234659A (zh) 2016-12-19 2019-09-13 特雷罗药物股份有限公司 用于敏感性分析的分析肽和方法
CN116606261A (zh) 2016-12-22 2023-08-18 美国安进公司 Kras g12c抑制剂及其使用方法
BR112019014127A2 (pt) 2017-02-08 2020-02-11 Eisai R&D Management Co., Ltd. Composição farmacêutica para tratamento de tumores
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
AU2019262599B2 (en) 2018-05-04 2023-10-12 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MA52564A (fr) 2018-05-10 2021-03-17 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
MX2020012731A (es) 2018-06-01 2021-02-22 Amgen Inc Inhibidores de kras g12c y metodos para su uso.
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
WO2019241089A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US12083114B2 (en) 2018-12-19 2024-09-10 Disarm Therapeutics, Inc. Inhibitors of SARM1 in combination with neuro-protective agents
CN120398830A (zh) 2018-12-20 2025-08-01 美国安进公司 Kif18a抑制剂
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
AU2019403488B2 (en) 2018-12-20 2025-07-24 Amgen Inc. KIF18A inhibitors
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
CN113412262A (zh) 2019-02-12 2021-09-17 大日本住友制药肿瘤公司 包含杂环蛋白激酶抑制剂的制剂
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
KR20210146287A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN113747895A (zh) 2019-03-22 2021-12-03 大日本住友制药肿瘤公司 包含pkm2调节剂的组合物和用其治疗的方法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
UA129871C2 (uk) 2019-05-21 2025-08-27 Емджен Інк. Тверді форми
CA3147451A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114401953A (zh) 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
US20220289724A1 (en) 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
EP4007638A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Pyridine derivatives as kif18a inhibitors
CA3155857A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CR20220240A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
JP2022553859A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
PH12022551102A1 (en) 2019-11-08 2023-11-20 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
EP4058453A1 (en) 2019-11-14 2022-09-21 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
AU2020383535A1 (en) 2019-11-14 2022-05-05 Amgen Inc. Improved synthesis of KRAS G12C inhibitor compound
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CN116209438A (zh) 2020-09-03 2023-06-02 锐新医药公司 使用sos1抑制剂治疗具有shp2突变的恶性疾病
CN116457358A (zh) 2020-09-15 2023-07-18 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
AR125782A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
JP2025500878A (ja) 2021-12-17 2025-01-15 ジェンザイム・コーポレーション Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
KR20250022133A (ko) 2022-06-10 2025-02-14 레볼루션 메디슨즈, 인크. 거대고리 ras 억제제
PE20251879A1 (es) 2022-10-14 2025-07-22 Black Diamond Therapeutics Inc Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
WO2024140850A1 (zh) * 2022-12-28 2024-07-04 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其医药用途
TW202504611A (zh) 2023-03-30 2025-02-01 美商銳新醫藥公司 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
US4057416A (en) * 1976-06-18 1977-11-08 Fmc Corporation 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
MY109202A (en) 1992-07-10 1996-12-31 Nihon Nohyaku Co Ltd Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
IL112721A0 (en) 1994-03-10 1995-05-26 Zeneca Ltd Azole derivatives
DE4425642A1 (de) * 1994-07-20 1996-01-25 Merck Patent Gmbh Partiell fluorierte Benzolderivate
KR20010082501A (ko) 1997-10-27 2001-08-30 개리 이. 프라이드만 4-아미노티아졸 유도체, 그 제조방법 및 싸이클린-의존성키나아제의 억제제로서의 이용방법
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
OA12532A (en) * 2000-11-28 2006-06-02 Pfizer Prod Inc Salts of a isothiazole-4-carboxamide and their useas anti-hyperproliferation agents.
CA2513140A1 (en) * 2003-01-27 2004-08-12 Pfizer Products Inc. Isothiazole derivatives

Also Published As

Publication number Publication date
BG65104B1 (bg) 2007-02-28
HUP0102422A3 (en) 2002-06-28
SA99200217B1 (ar) 2006-05-06
US6548526B2 (en) 2003-04-15
EA004935B1 (ru) 2004-10-28
US20010020034A1 (en) 2001-09-06
UY25619A1 (es) 2000-02-23
EP1084114B1 (en) 2004-09-08
AP9901560A0 (en) 1999-06-30
TNSN99106A1 (fr) 2005-11-10
NO318798B1 (no) 2005-05-09
PA8472301A1 (es) 2000-09-29
HRP20000835B1 (hr) 2008-01-31
GT199900070A (es) 2000-11-10
HRP20000835A2 (en) 2001-12-31
NO20006071D0 (no) 2000-11-30
CA2333703A1 (en) 1999-12-09
KR100392434B1 (ko) 2003-07-22
AU3342199A (en) 1999-12-20
AR016725A1 (es) 2001-07-25
MY130668A (en) 2007-07-31
DE69920009T2 (de) 2005-09-15
ES2226368T3 (es) 2005-03-16
DE69920009D1 (de) 2004-10-14
CN1303380A (zh) 2001-07-11
CA2333703C (en) 2005-06-14
CA2475113A1 (en) 1999-12-09
AP1309A (en) 2004-09-14
IL138776A0 (en) 2001-10-31
SK17782000A3 (sk) 2001-08-06
TR200003478T2 (tr) 2001-03-21
CN1616386A (zh) 2005-05-18
CN1172918C (zh) 2004-10-27
US7790902B2 (en) 2010-09-07
JP3735254B2 (ja) 2006-01-18
PE20000568A1 (es) 2000-07-08
CZ298559B6 (cs) 2007-11-07
US7405218B2 (en) 2008-07-29
HN1999000080A (es) 1999-09-29
PT1084114E (pt) 2004-12-31
HK1036982A1 (en) 2002-01-25
ATE275553T1 (de) 2004-09-15
YU70100A (sh) 2004-07-15
HUP0102422A2 (hu) 2002-05-29
TW561154B (en) 2003-11-11
SK286405B6 (sk) 2008-09-05
BG104998A (en) 2001-07-31
KR20010052516A (ko) 2001-06-25
US20080300249A1 (en) 2008-12-04
BR9910900B1 (pt) 2013-09-17
US6235764B1 (en) 2001-05-22
SI1084114T1 (en) 2005-02-28
US20030149048A1 (en) 2003-08-07
EA200001146A1 (ru) 2001-04-23
OA11504A (en) 2004-05-17
IS5690A (is) 2000-10-27
JP2002517384A (ja) 2002-06-18
PL198151B1 (pl) 2008-05-30
BR9910900A (pt) 2001-02-13
WO1999062890A1 (en) 1999-12-09
PL344691A1 (en) 2001-11-19
CZ20004451A3 (en) 2001-05-16
MA26638A1 (fr) 2004-12-20
ID27006A (id) 2001-02-22
NO20006071L (no) 2000-11-30
IS2269B (is) 2007-07-15
EP1084114A1 (en) 2001-03-21
UA60365C2 (uk) 2003-10-15
CA2475113C (en) 2008-03-18
ZA993752B (en) 2000-12-04
CO5011121A1 (es) 2001-02-28
JP2005002122A (ja) 2005-01-06
NZ507009A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
GEP20084337B (h)
JP2001509377A5 (h)
BRPI9917862A2 (h)
JP2001521259A5 (h)
IN2000CH00772A (h)
JP2003521818A5 (h)
JP2598030C (h)
IN188755B (h)
IN190298B (h)
IN187977B (h)
JP2545811C (h)
JP2580682C (h)
JP2541270C (h)
JP2543683C (h)
CN3074964S (h)
CN3073964S (h)
CN3077504S (h)
CN3077125S (h)
CN3076976S (h)
BY4669C1 (h)
CN3075658S (h)
CN3075297S (h)
CN3075068S (h)
CN3074993S (h)
CN3077894S (h)